 | Up a level |
Kiss, Bernhard; Wyatt, Alexander W; Douglas, James; Skuginna, Veronika Olga; Mo, Fan; Anderson, Shawn; Rotzer, Diana; Fleischmann, Achim; Genitsch Gratwohl, Vera; Hayashi, Tetsutaro; Neuenschwander, Maja; Buerki, Christine; Davicioni, Elai; Collins, Colin; Thalmann, George; Black, Peter C; Seiler, Roland (2017). Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy. Scientific Reports, 7(42713), p. 42713. Nature Publishing Group 10.1038/srep42713
Tschui, Joëlle; Vassella, Erik; Bandi Hess, Nora; Baumgartner, Ulrich; Genitsch Gratwohl, Vera; Rotzer, Diana; Seiler, Roland; Thalmann, George; Fleischmann, Achim (2015). Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer. Virchows Archiv, 466(6), pp. 703-710. Springer 10.1007/s00428-015-1729-4
Fleischmann, Achim; Saramäki, Outi R; Zlobec, Inti; Rotzer, Diana; Genitsch Gratwohl, Vera; Seiler, Roland; Visakorpi, Tapio; Thalmann, George (2014). Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers. Prostate, 74(16), pp. 1647-1654. Wiley-Blackwell 10.1002/pros.22882
Seiler, Roland; Thalmann, George N.; Rotzer, Diana; Perren, Aurel; Fleischmann, Achim (2014). CCND1/CyclinD1 status in metastasizing bladder cancer: a prognosticator and predictor of chemotherapeutic response. Modern pathology, 27(1), pp. 87-95. Nature Publishing Group 10.1038/modpathol.2013.125
Fleischmann, Achim; Rotzer, Diana; Seiler, Roland; Studer, Urs E; Thalmann, George N (2011). Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. European urology, 60(2), pp. 350-7. Amsterdam: Elsevier 10.1016/j.eururo.2011.05.035
